|This article is part of Rheumatology Advisor’s 2017 in-depth coverage of ACR, which took place in San Diego, CA. Our staff will be reporting on the latest treatment advancements and research initiatives for spondyloarthritis. Click here to read more of Rheumatology Advisor‘s conference coverage.|
SAN DIEGO — Administration of abatacept may improve patient-reported outcomes (PROs) in individuals with active psoriatic arthritis and elevated levels of C-reactive protein (CRP), irrespective of tumor necrosis factor inhibitor (TNFi) treatment history, according to a study presented at the American College of Rheumatology 2017 Annual Meeting, held November 3-8 in San Diego, California.
The researchers retrospectively evaluated PROs in patients included in the ASTRAEA study (ClinicalTrials.gov identifier: NCT01860976) and randomly assigned participants to receive either abatacept weekly (125 mg subcutaneously) or placebo for a period of 24 weeks; physical and mental status, quality of life, and therapy-related fatigue were evaluated after 16 and 24 weeks of treatment.
Improvements in PROs for the physical and mental component summary were higher in study participants receiving abatacept vs placebo at 16 weeks. Overall, improvements were deemed significant for physical and mental scores at 16 weeks, and for quality of life at both 16 and 24 weeks.
In addition, improvements in the domain scores of both physical and mental functioning were similar at 24 weeks, but higher in the abatacept vs placebo group. At 16 weeks, all PROs were improved in both the abatacept and placebo groups for study participants with or without a history of TNFi treatment.
The use of abatacept is associated with numerically higher improvements in PROs in patients with active psoriatic arthritis, “with larger benefits in the elevated CRP subpopulation and regardless of prior TNFi exposure.”
|Visit Rheumatology Advisor’s conference section for our in-depth focus on spondyloarthritis at ACR 2017.|
Strand V, Alemao E, Lehman T, et al. Improved patient-reported outcomes in psoriatic arthritis patients treated with abatacept: results from a phase III trial. Presented at: American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) 2017 Annual Meeting; November 3-8, 2017; San Diego, CA. Abstract 595.